ArticleOdontology2026
Effectiveness of photobiomodulation in the treatment of xerostomia in type II diabetic patients.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06703372 (Effectiveness Of Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness Of Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients (A Randomized, Controlled Clinical Trial)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effect of diode laser photobiomodulation in the treatment of xerostomia among diabetics. A randomized controlled clinical trial was conducted on 52 diabetic patients experiencing xerostomia. Participants were randomly assigned to a test group, receiving diode laser application or to a control group, receiving no active treatment. Unstimulated and stimulated salivary flow rates were assessed at baseline, 2, 4, 6 and 12 weeks. Subjective xerostomia symptoms were evaluated using the Xerostomia Inventory. In the test group, unstimulated salivary flow rose from 0.13 ± 0.04 mL/min at baseline to 0.25 ± 0.06 at week 12, and stimulated flow from 0.51 ± 0.09 to 1.00 ± 0.27 (p < 0.001 for both). Unstimulated flow in the control group increased from 0.12 ± 0.05 to 0.14 ± 0.05, and stimulated flow from 0.48 ± 0.10 to 0.54 ± 0.11, with significance detected only at week 12. Subjective xerostomia scores also improved in the test group, decreasing from 12.19 ± 2.02 to 8.48 ± 1.83 (p < 0.001), while no significant change was noted in the control group. Photobiomodulation with a 980 nm diode laser might be an effective and safe therapeutic modality to improve salivary flow and xerostomia symptoms in diabetic patients.Trial registration:The study has been registered at ClinicalTrials.gov (NCT06703372), 22/11 2024.
Indexed as
Identifiers
42474921What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.